Serum cytokine levels in breast cancer patients during neoadjuvant treatment with bevacizumab

Serum cytokine levels in breast cancer patients during neoadjuvant treatment with bevacizumab

A high concentration of circulating vascular endothelial growth factor (VEGF) in cancer patients is associated with an aggressive tumor phenotype. Here, serum levels of 27 cytokines and blood cell counts were assessed in breast cancer patients receiving neoadjuvant chemotherapy with or without bevac...

Full description

Bibliographic Details
Main Authors: Shakila Jabeen, Manuela Zucknick, Marianne Nome, Ruth Dannenfelser, Thomas Fleischer, Surendra Kumar, Torben Lüders, Hedda von der Lippe Gythfeldt, Olga Troyanskaya, Jon Amund Kyte, Anne-Lise Børresen-Dale, Bjørn Naume, Xavier Tekpli, Olav Engebraaten, Vessela Kristensen
Format: Article
Language:English
Published: Taylor & Francis Group 2018-11-01
Series:OncoImmunology
Subjects:
bevacizumab
vegf-a
neoadjuvant
cytokines
immunity
Online Access:http://dx.doi.org/10.1080/2162402X.2018.1457598

Internet

http://dx.doi.org/10.1080/2162402X.2018.1457598

Similar Items